The dynamics of the multiple sclerosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as CNM-Au8 (Clene Nanomedicine), Tolebrutinib (Sanofi), Evobrutinib/M2951 (Merck Healthcare KGaA), NeuroVax (Immune Response BioPharma), and many others. In addition, the rising research and prevalence will also fuel the multiple sclerosis market during the forecast period of 2023–2032.
LAS VEGAS, July 27, 2023 /PRNewswire/ -- DelveInsight's Multiple Sclerosis Market Insights report includes a comprehensive understanding of current treatment practices, multiple sclerosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Multiple Sclerosis Market Report
- As per DelveInsight analysis, the multiple sclerosis market is expected to grow positively at a significant CAGR during the study period (2019–2032).
- As per the assessment of DelveInsight, the total prevalent cases of multiple sclerosis in the 7MM were found to be 1.2 million in 2022, which are expected to increase during the study period (2019–2032).
- Globally, leading multiple sclerosis companies such as Immune Response BioPharma, Inc., Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., Bristol-Myers Squibb, TG Therapeutics, Inc., Hoffmann-La Roche, Atara Biotherapeutics, Immunic AG, Celgene, Anokion SA, Sanofi, Actelion, Biogen, Supernus Pharmaceuticals, Inc., GeNeuro SA, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, RemeGen Co., Ltd., Antisense Therapeutics, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, Solstice Neurosciences, ProJenX, and others are developing novel multiple sclerosis drugs that can be available in the multiple sclerosis market in the coming years.
- Some key therapies for multiple sclerosis treatment include NeuroVax, CNM-Au8, [F-18]PBR06, IMS001, Tolebrutinib (SAR442168), 11C-BMS-986196, Ublituximab, Ocrelizumab, ATA188, IMU-838, RPC-1063, ANK-700, SAR441344 IV, Ponesimod, BIIB017, MYOBLOC, Prosetin, and others.
Discover which therapies are expected to grab the major multiple sclerosis market share @ Multiple Sclerosis Market Report
Multiple Sclerosis Overview
Multiple sclerosis is a chronic neurological disorder that affects the central nervous system. It is characterized by the immune system mistakenly attacking the protective covering of nerve fibers, known as myelin, leading to communication problems between the brain and the rest of the body. The exact cause of multiple sclerosis is still unknown, but it is believed to involve a combination of genetic and environmental factors.
The symptoms of multiple sclerosis can vary widely from person to person and depend on the location and extent of nerve damage. Some common multiple sclerosis symptoms include fatigue, difficulty walking, numbness or tingling in the limbs, muscle weakness, problems with coordination and balance, blurred or double vision, dizziness, and cognitive impairment. The multiple sclerosis symptoms can come and go or worsen over time, leading to periods of relapse and remission. Diagnosing multiple sclerosis can be challenging as there is no specific test that can confirm the presence of the disease definitively. Instead, doctors rely on a combination of medical history, neurological examinations, and diagnostic tests. MRI is often used to detect areas of myelin damage or inflammation in the CNS. Other tests such as spinal tap may be performed to analyze the cerebrospinal fluid for specific markers associated with multiple sclerosis.
Multiple Sclerosis Epidemiology Segmentation
The multiple sclerosis epidemiology section provides insights into the historical and current multiple sclerosis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The multiple sclerosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Multiple Sclerosis Prevalent Cases
- Multiple Sclerosis Prevalence Based on Gender
- Multiple Sclerosis Phenotype-specific Prevalent Cases
- Multiple Sclerosis Prevalence Based on Age
- Extent of Disability (EDSS) in Multiple Sclerosis
Multiple Sclerosis Treatment Market
Although there is no known cure for multiple sclerosis, there are various treatment options available to manage the symptoms and slow down the progression of the disease. Multiple sclerosis treatment approaches typically focus on three main aspects: modifying the disease course, managing symptoms, and providing supportive care. Disease-modifying therapies (DMTs) are used to reduce the frequency and severity of relapses and slow down the accumulation of disability. These medications work by modifying the immune system's response to reduce inflammation and the immune attack on the nervous system.
Symptom management involves addressing specific multiple sclerosis symptoms such as fatigue, muscle weakness, spasticity, pain, and cognitive difficulties through various interventions, including medication, physical therapy, occupational therapy, and lifestyle modifications. Supportive care encompasses a holistic approach that includes rehabilitation, emotional support, and education to help individuals with multiple sclerosis maintain their overall well-being and quality of life. Multiple sclerosis treatment plans are often personalized to suit individual needs, and close monitoring and regular follow-ups are crucial to ensuring the effectiveness of the chosen therapies. Research and advancements in multiple sclerosis treatment continue to offer hope for improved outcomes and better management strategies in the future.
Furthermore, rehabilitation programs play a vital role in multiple sclerosis treatment by addressing physical, cognitive, and emotional challenges. These programs aim to maximize function, improve quality of life, and manage fatigue and depression commonly associated with multiple sclerosis. Psychosocial support, counseling, and support groups can provide valuable emotional support and coping strategies for individuals living with multiple sclerosis and their families.
To know more about multiple sclerosis treatment, visit @ Multiple Sclerosis Treatment Drugs
Key Multiple Sclerosis Therapies and Companies
- NeuroVax: Immune Response BioPharma, Inc.
- CNM-Au8: Clene Nanomedicine
- [F-18]PBR06: Genzyme
- IMS001: ImStem Biotechnology/Rho, Inc.
- Tolebrutinib (SAR442168): Sanofi
- 11C-BMS-986196: Bristol-Myers Squibb
- Ublituximab: TG Therapeutics, Inc.
- Ocrelizumab: Hoffmann-La Roche
- ATA188: Atara Biotherapeutics
- IMU-838: Immunic AG
- RPC-1063: Celgene
- ANK-700: Anokion SA
- SAR441344 IV: Sanofi
- Ponesimod: Actelion
- BIIB017: Biogen
- MYOBLOC: Supernus Pharmaceuticals, Inc./Solstice Neurosciences
- Prosetin: ProJenX
Learn more about the FDA-approved drugs for multiple sclerosis @ Drugs for Multiple Sclerosis Treatment
Multiple Sclerosis Market Dynamics
The market dynamics of multiple sclerosis have been undergoing significant changes in recent years. Multiple sclerosis, a chronic autoimmune disease affecting the central nervous system, has witnessed a surge in research and development activities, resulting in an expanding range of treatment options. The introduction of disease-modifying therapies (DMTs) has revolutionized the management of multiple sclerosis, providing patients with more effective and personalized treatment approaches. Additionally, technological advancements have led to the development of innovative diagnostic tools, enabling early detection and accurate monitoring of the disease.
Moreover, there has been a growing emphasis on patient-centric care, with a focus on improving quality of life and addressing the diverse needs of individuals living with multiple sclerosis. These evolving multiple sclerosis market dynamics, coupled with a rising prevalence of multiple sclerosis globally, have fueled competition among pharmaceutical companies, leading to increased investments in novel therapeutic interventions and a drive for improved efficacy, safety, and convenience in multiple sclerosis treatments. As a result, the multiple sclerosis market is anticipated to witness sustained growth and innovation in the coming years, ultimately benefiting patients by providing them with a wider array of treatment options and improved outcomes.
In spite of the promising market dynamics, there are several barriers that impact the multiple sclerosis market. Firstly, the high cost of multiple sclerosis treatments poses a significant challenge, limiting access for many patients. The expenses associated with disease-modifying therapies (DMTs) and supportive care can place a substantial financial burden on individuals and healthcare systems. This barrier is particularly significant in countries with limited healthcare resources or where insurance coverage is inadequate.
Another barrier is the complex nature of multiple sclerosis and its heterogeneous presentation, which makes it challenging to develop universally effective therapies. Additionally, the regulatory landscape and reimbursement policies can impact market dynamics. The stringent regulatory requirements and lengthy approval processes for new therapies can delay the availability of innovative treatments. Moreover, variations in reimbursement policies across different regions or healthcare systems can influence market access and adoption of novel therapies, creating discrepancies in patient care.
Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key Multiple Sclerosis Companies | Immune Response BioPharma, Inc., Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., Bristol-Myers Squibb, TG Therapeutics, Inc., Hoffmann-La Roche, Atara Biotherapeutics, Immunic AG, Celgene, Anokion SA, Sanofi, Actelion, Biogen, Supernus Pharmaceuticals, Inc., GeNeuro SA, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, RemeGen Co., Ltd., Antisense Therapeutics, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, Solstice Neurosciences, ProJenX, and others |
Key Multiple Sclerosis Therapies | NeuroVax, CNM-Au8, [F-18]PBR06, IMS001, Tolebrutinib (SAR442168), 11C-BMS-986196, Ublituximab, Ocrelizumab, ATA188, IMU-838, RPC-1063, ANK-700, SAR441344 IV, Ponesimod, BIIB017, MYOBLOC, Prosetin, and others |
Scope of the Multiple Sclerosis Market Report
- Therapeutic Assessment: Multiple Sclerosis current marketed and emerging therapies
- Multiple Sclerosis Market Dynamics: Conjoint Analysis of Emerging Multiple Sclerosis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Multiple Sclerosis Market Access and Reimbursement
Discover more about multiple sclerosis drugs in development @ Multiple Sclerosis Clinical Trials
Table of Contents
1. | Multiple Sclerosis Market Key Insights |
2. | Multiple Sclerosis Market Report Introduction |
3. | Multiple Sclerosis Market Overview at a Glance |
4. | Multiple Sclerosis Market Executive Summary |
5. | Disease Background and Overview |
6. | Multiple Sclerosis Treatment and Management |
7. | Multiple Sclerosis Epidemiology and Patient Population |
8. | Patient Journey |
9. | Multiple Sclerosis Marketed Drugs |
10. | Multiple Sclerosis Emerging Drugs |
11. | Seven Major Multiple Sclerosis Market Analysis |
12. | Multiple Sclerosis Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, among others.
Relapsing Multiple Sclerosis Pipeline
Relapsing Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing multiple sclerosis companies, including ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, among others.
Chronic Progressive Multiple Sclerosis Pipeline
Chronic Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic progressive multiple sclerosis companies, including Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, among others.
Primary Progressive Multiple Sclerosis Pipeline
Primary Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary progressive multiple sclerosis companies, including Atara Biotherapeutics, AB Science, Sanofi, MediciNova, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:
Voltar noticias em Inglês